Celiac Disease Treatment Market Report 2025

The celiac disease treatment market size has grown strongly in recent years. It will grow from $0.61 billion in 2024 to $0.66 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to rise in prevalence of celiac disease, increase in awareness and diagnosis rates, growth in demand for non-dietary treatment options, strong pipeline of innovative therapies, supportive regulatory initiatives, and increase in investment from pharmaceutical companies.

The celiac disease treatment market size is expected to see strong growth in the next few years. It will grow to $0.94 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising global prevalence of celiac disease, increasing awareness and diagnosis rates, ongoing clinical trials for novel treatments, growing demand for gluten-free alternatives, supportive regulatory initiatives for orphan diseases, and rising healthcare expenditure. Major trends in the forecast period include adoption of novel non-dietary therapies, advancements in enzyme supplements, personalized medicine approaches, development of peptide-based immunotherapies, improved diagnostic tools, and advancements in clinical trials.

The forecast of 9.3% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. gastroenterology practices by inflating prices of gluten-free enzyme supplements manufactured in Italy and Canada, resulting in limited celiac management options and higher digestive health care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of diabetes is anticipated to drive the expansion of the celiac disease treatment market in the coming years. Diabetes is a chronic condition characterized by the body's inability to properly regulate blood glucose levels. This rise in diabetes prevalence is linked to overlapping dietary management needs between diabetes and celiac disease, as both require careful regulation of food intake to manage symptoms and prevent complications. Celiac disease treatments support individuals with diabetes by promoting a gluten-free diet, which enhances digestive health and nutrient absorption, aiding in improved blood sugar control. For instance, in June 2024, the National Health Service, a UK-based government agency, reported that approximately 3,615,330 individuals registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023, reflecting an 18% increase from 3,065,825 cases in 2022. Thus, the increasing prevalence of diabetes is boosting the celiac disease treatment market.

Leading companies in the celiac disease treatment market are prioritizing the development of innovative oral therapies, such as small molecule drugs, to block immune responses to gluten, enhance treatment adherence, and provide alternatives to restrictive gluten-free diets. Small molecule therapies are compact drugs capable of penetrating cells to target proteins or enzymes that cause disease. For example, in February 2025, Immunic Inc., a US-based biotech firm, introduced IMU-856, a small molecule therapy that elevates endogenous glucagon-like peptide-1 (GLP-1) levels. This treatment improves the integrity of the intestinal barrier in patients with celiac disease, enhances nutrient absorption, and reduces symptoms - all without suppressing immune function.

In October 2022, Takeda Pharmaceutical Company Limited, a pharmaceutical company based in Japan, formed a partnership with Zedira GmbH and Dr. Falk Pharma to develop TAK-227 (ZED1227), an oral treatment for celiac disease. This therapy is designed to target intestinal inflammation and promote mucosal healing, representing a promising new option for patients. Zedira GmbH is a German biotech firm specializing in therapies for celiac disease and other transglutaminase-related conditions. Dr. Falk Pharma, also based in Germany, focuses on pharmaceutical solutions for gastrointestinal disorders.

Major players in the celiac disease treatment market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceuticals Company Ltd., Amgen Inc., General Mills Inc., Viatris Inc., Teva Pharmaceutical Inc., Nestlé Health Science, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Pharmaceuticals Inc., Glenmark Pharmaceuticals Company Ltd., West-Ward Pharmaceuticals Company Ltd, Innovate Biopharmaceutical, Acto Biosciences, ImmunogenX.

North America was the largest region in the celiac disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in celiac disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the celiac disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The celiac disease treatment market consists of sales of gluten-free food products, vitamin D, Vitamin B12, and folic acid supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The Business Research Company that provides celiac disease treatment market statistics, including the celiac disease treatment industry global market size, regional shares, competitors with the celiac disease treatment market share, detailed celiac disease treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the celiac disease treatment industry. This celiac disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Celiac disease treatment focuses on managing the autoimmune reaction to gluten, which damages the small intestine and impairs nutrient absorption. The primary approach is a strict gluten-free diet, which eliminates foods and products containing wheat, barley, rye, and other gluten-containing grains. This treatment reduces symptoms, heals the small intestine lining, and prevents long-term health complications.

The main types of treatment for celiac disease include vitamins and minerals, gluten-degrading enzymes, symptomatic treatments, and other approaches. Vitamins and minerals are essential micronutrients that support key bodily functions, such as immune response, energy production, and bone health. Enzyme therapies address symptoms such as distension, diarrhea, anorexia, bloating, gas, and fatigue. Diagnostic methods for celiac disease include serological tests, genetic testing, and intestinal biopsy. These treatments and diagnostic services are provided through various distribution channels, including hospitals, research centers, clinics, and others.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.